

Awards 2025

Seven awards for particularly promising clinical trials

At its biannual meeting in Interlaken, the Swiss Cancer Institute awarded seven grants totalling **CHF 210,000** to particularly promising clinical cancer research trials.

Sponsor	Award Name	Award Amount	Winner	Abstract
AbbVie	Swiss Cancer Institute / AbbVie Award for digital innovation in Oncology & Hematology Award	CHF 30,000	Giuseppe Salfi MD, EOC	Exploiting Integrated Clinical and Molecular Prostate Cancer Data for Better Care
Astellas	Swiss Cancer Institute / Astellas GU-Oncology Award	CHF 30,000	Bianca Cali' Phd, IOR	Targeting PMN-MDSC secretome for prostate cancer therapy
Bristol Myers Squibb (BMS)	Swiss Cancer Institute / BMS HEM Pioneer Grant	CHF 20,000	Guido Ghilardi MD, EOC	EVALUATION OF SECOND PRIMARY MYELOID MALIGNANCIES AFTER CHIMERIC ANTIGEN RECEPTOR T CELL IMMUNOTHERAPY
Gilead	Swiss Cancer Institute / Gilead Expanding Horizons in Oncology Award	CHF 40,000	Dr. med. Nadia Maggi, USB	Survival and axillary recurrence in patients with sentinel node-positive breast cancer
Incyte	Swiss Cancer Institute / Incyte HERo in Science Award	CHF 30,000	Stefanie Fischer MD, KSG	Terbinafine for biochemically recurrent Prostate Cancer (TerbinaPro)
Novartis	Swiss Cancer Institute / Novartis Together for Patients Award	CHF 30,000	Nicolas Dulguerov MD, HUG	Reducing the burden of head and neck squamous cell carcinomas, towards more personalized medicine to improve quality of life
Roche	Swiss Cancer Institute / Roche Young Investigator Award	CHF 30,000	Dr. med. Kevin Hofer, USZ	Real-time breath analysis for the detection of invasive fungal infections in neutropenic high-risk patients (REDEFINE)